Category Archives: Deals

Pfizer to Acquire King Pharmaceuticals

By Jennifer Ringler | Published: October 12, 2010
The merger, announced on Tuesday, will cost Pfizer $3.6 billion. Pfizer and King Pharmaceuticals announced on Tuesday they have entered into a definitive friendly merger agreement. Under the terms, Pfizer will acquire King, a diversified specialty pharmaceutical company based in Tennessee, for $3.6 billion in cash, or $14.25 per share. The company emphasized the deal is not [...]
Posted in Deals | Tagged , | Leave a comment

Affordable Access to HIV Meds on the Way

By Jennifer Ringler | Published: October 1, 2010
UNITAID’s Medicines Patent Pool seeks to bring costly HIV/AIDS treatments and other essential drugs to low-income countries by requiring patent-holders to license their technologies to generics manufacturers. Will pledges of support from the NIH bring some of these patent-holders back to the negotiating table? A new way for patients to have access to affordable HIV and [...]
Also posted in Manufacturing | Tagged , , , | Leave a comment

Endo Pharmaceuticals Acquires Qualitest for $1.2 Billion

By Jennifer Ringler | Published: September 28, 2010
The biotech aims to deliver more comprehensive healthcare solutions across its diversified businesses in branded pharmaceuticals, generics, and devices & services in key therapeutic areas with this deal. Endo Pharmaceuticals has entered into an agreement to acquire privately held Qualitest Pharmaceuticals for approximately $1.2 billion in cash. Qualitest, the sixth-largest US generics company as measured by [...]
Posted in Deals | Tagged , | Leave a comment

What Is Behind the Genzyme Job Cuts?

By Julian Upton | Published: September 15, 2010
Troubled biotech Genzyme’s (Cambridge, MA) planned elimination of over 1,000 jobs (10% of its 12,800 workforce, according to the Boston Globe) over the next 15 months is not related to the takeover bid from French giant Sanofi Aventis, the company has said.
Also posted in Global, Strategy | Tagged , , , , , , | Leave a comment

MedImmune Bets Its Fate on “Biobetters”

By Walter Armstrong | Published: September 9, 2010
AstraZeneca’s biologics shop makes a decisive move in the biosimilars market. MedImmune, the biologics shop bought by AstraZeneca (AZ) for a staggering $15 billion in 2007 promising one new drug a year for the foundering British firm, has made precious little news since the deal. But all of a sudden the post-Labor Day wires were crackling [...]
Also posted in Biotech, Global, R&D, Strategy | Tagged , , , , , , | 1 Comment